Qual é o preço para Molecular Partners AG (MOLN)

O preço para Molecular Partners AG (MOLN) é $4.43

Qual é a capitalização de mercado para Molecular Partners AG (MOLN)

A capitalização de mercado para Molecular Partners AG (MOLN) é $166.36M

Receita de Molecular Partners AG (MOLN)

Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.

Ano	Receita	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Receita

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Receita	Diferença de Receita	País
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Receita

Diferença de Receita

País